UPRCCC/MDACC: Partnership for Excellence in Cancer Research (1 of 2)

描述（由申请人提供）：这是波多黎各大学（UPR）和德克萨斯大学MD安德森癌症中心（MDACC）之间癌症研究卓越合作伙伴关系的更新申请。该伙伴关系提出了结构化倡议，以进一步加强这两个机构的研究基础设施 减少癌症健康差距的负担。该奖项的资金将用于支持两个完整的和一个试点研究项目。第一个完整的项目研究了西非血统在前列腺癌风险和侵略性中的作用。初步数据显示，一些祖先遗传标记，体重指数和社会经济地位与高级别前列腺癌相关。第二个完整的项目集中在基于磁性纳米粒子的卵巢癌热疗。试点项目数据显示，当用纳米颗粒治疗时，相关肿瘤大小显著减小。该试点研究是在肿瘤诊所进行的戒烟干预。这些项目共同组成了一个多学科研究组合，代表了转化研究连续体的T1至T3阶段。伙伴关系资金还将用于：1）加强现有的合作并建立新的合作; 2）重组培训渠道，包括对癌症医学感兴趣的医生，科学家和医生科学家的定制职业发展轨道，以加速为UPR综合癌症中心（UPRCCC）培养足够数量的教师; 3）实施癌症教育课程;维持和扩大推广方案，包括核心服务和旨在减轻波多黎各人结肠直肠癌负担的推广研究项目。迄今为止，伙伴关系已建立了一个充满活力的协作小组，致力于巩固和稳定发展中的基础设施 新建成的UPRCCC研究中心（2009年6月开放）证明了UPRCCC的存在; UPRCCC医院将于2016年完工。为第二次延长提供资金对于巩固和扩大伙伴关系在过去十年中取得的巨大势头和成功至关重要。该伙伴关系准备实现其长期目标，将UPRCCC定位为解决影响西班牙裔人口的癌症连续体（预防，早期发现，诊断，治疗和生存）健康差距的领跑者。 相关性：这一更新旨在促进和支持普遍定期审议与MDACC之间的现有合作。通过解决美国西班牙裔人群中存在的癌症发病率，患病率，死亡率和负担的差异，该伙伴关系致力于通过癌症研究，培训，教育和宣传工作来减少这些差异。伙伴关系的贡献还将通过发展训练有素的西班牙裔癌症研究人员来帮助建立一个更强大的国家癌症计划。

DESCRIPTION (provided by applicant): This is a renewal application for the Partnership for Excellence in Cancer Research between The University of Puerto Rico (UPR) and The University of Texas MD Anderson Cancer Center (MDACC). The Partnership proposes structured initiatives to further enhance the research infrastructure within these two institutions to reduce the burden of cancer health disparities. Funds granted in this award will be used to support two full and one pilot research projects. The first full project examines the role of West African ancestry in prostate cancer risk and aggressiveness. Pilot data show an association of several ancestral genetic markers, body mass index, and socioeconomic status with higher-grade prostate cancer. The second full project focuses on magnetic nanoparticle based hyperthermia for ovarian cancer. Pilot project data show a marked decrease in the associated tumor size when treated with nanoparticles. The pilot study is a smoking cessation intervention in oncology clinics. Together, these projects comprise a multidisciplinary research portfolio representing the T l to T3 stages of the translational research continuum. Partnership funds will also be used to: 1) enhance existing collaborations and establish new collaborations; 2) restructure the training pipeline to include customized career development tracks for physicians, scientists and physician scientists interested in cancer medicine to accelerate the development of a critical mass of faculty for the UPR Comprehensive Cancer Center (UPRCCC); 3) implement a cancer education curriculum; and 4) maintain and expand the Outreach Program, including core services and an outreach research project designed to reduce the burden of colorectal cancer among Puerto Ricans. Thus far, the Partnership has established a dynamic collaborative team that is working towards fortifying and stabilizing the developing infrastructure at the UPRCCC as evidenced by a newly constructed UPRCCC Research Center (opened 6/2009); the UPRCCC hospital will be completed in 2016. Funding for a second renewal is critical to cement and build on the substantial momentum and success achieved by the Partnership over the last ten years. The Partnership is poised to fulfill its long-term goal of positioning the UPRCCC to become a frontrunner in addressing health disparities that affect Hispanic populations across the cancer continuum (prevention, early detection, diagnosis, treatment and survivorship). RELEVANCE: This renewal seeks to foster and support an existing collaboration between the UPR and MDACC. By addressing differences in incidence, prevalence, mortality, and burden of cancer that exist among Hispanic populations in the US, the Partnership strives to reduce these disparities through efforts in Cancer Research, Training, Education and Outreach. Partnership contributions will also aid in building a stronger national cancer program through the development of a pipeline of well-trained, Hispanic cancer researchers.